Astec Lifesciences Limited (ASTEC) AI Stock Analysis

• Market Cap: ₹12.80B
• Dividend Yield: N/A
• Average Volume (3M): 412.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: 1.54%
• EPS Growth: -8.04%
• Country: IN
• Employees: 606
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): -6.30
• Shares Outstanding: 22,281,660
• 10 Day Avg. Volume: 47,730
• 30 Day Avg. Volume: 412,490
• PEG Ratio: -0.06
• Price to Book (P/B): 6.10
• Price to Sales (P/S): 3.76
• P/FCF Ratio: -47.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ₹580.00 ▼(-17.56% Downside)

The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenue, negative margins, and liquidity issues. While technical analysis shows positive momentum, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, resulting in a moderate overall score.

Positive Factors

Diversified value-chain exposure

Selling both active ingredients/intermediates and formulated products gives the company multiple, enduring revenue channels. This vertical exposure reduces reliance on a single product tier, supports cross-selling and pricing flexibility, and helps sustain volumes across agricultural cycles.

In-house manufacturing of technicals and formulations

Owning manufacturing capability for technicals, intermediates and formulations is a durable operational asset. It supports quality control, margin capture, faster customer responsiveness and potential contract-manufacturing opportunities that underpin long-term B2B relationships in agrochemicals.

Positive stockholders' equity

Maintaining positive equity provides a solvency buffer and underpins the firm’s ability to operate and access capital. This structural cushion reduces immediate bankruptcy risk and supports continuity while management addresses leverage and cash flow weaknesses.

Negative Factors

Declining revenue and profitability

Sustained revenue decline and negative net margins erode internal funding for capex and working capital, weaken competitive positioning, and pressure long-term supplier/customer relationships. Persistent profitability deficits hamper reinvestment and strategic initiatives over months.

Negative operating and free cash flow

Consistently negative operating and free cash flow indicates the business struggles to convert earnings into cash, forcing reliance on external financing. This structural cash shortfall constrains capex, inventory funding and resilience to demand shocks over the medium term.

High and rising leverage

Increasing debt-to-equity and falling equity ratios raise solvency and refinancing risk. Elevated leverage increases fixed interest obligations, reduces financial flexibility for strategic investments, and heightens vulnerability to cyclical downturns in the agrochemical market.

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec Lifesciences Limited (ASTEC) is a leading manufacturer and supplier of agrochemicals and pharmaceutical intermediates based in India. The company operates primarily in the agrochemical sector, focusing on the production of herbicides, fungicides, insecticides, and other crop protection products. Additionally, ASTEC is involved in the development of pharmaceutical intermediates and specialty chemicals, catering to both domestic and international markets. Leveraging its strong research and development capabilities, the company aims to provide innovative solutions for sustainable agriculture and healthcare.

How the Company Makes Money

Astec Lifesciences generates revenue primarily through the sale of its agrochemical products and pharmaceutical intermediates. The company's revenue model is built on manufacturing and distributing a diverse range of crop protection chemicals, which are sold to agricultural businesses and distributors. Key revenue streams include the sale of branded and generic agrochemicals, contract manufacturing services for third parties, and the export of products to international markets. Significant partnerships with global agricultural firms enhance its market reach and contribute to earnings through collaborative projects and joint ventures. Additionally, the company's focus on research and development allows it to introduce new products, thereby expanding its market presence and driving revenue growth.

Astec Lifesciences Limited Financial Statement Overview

Summary

Astec Lifesciences Limited faces significant financial challenges. The income statement highlights declining revenue and profitability, with negative margins impacting overall performance. The balance sheet shows high leverage and decreasing equity ratios, increasing financial risk. Cash flow difficulties, marked by negative free cash flow, further exacerbate the situation, suggesting liquidity constraints and a need for strategic financial management.

Income Statement

The income statement shows a decline in revenue from 2023 to 2025, with a significant drop in gross profit and net income, resulting in negative margins. The company has experienced negative net profit margins in the most recent years, indicating profitability issues. The revenue growth has been negative, reflecting a challenging market environment or operational difficulties.

Balance Sheet

The balance sheet indicates high leverage with an increasing debt-to-equity ratio over the years, reflecting financial risk. The equity ratio has also decreased, signaling reduced asset backing by equity. Although the company maintains a positive stockholder's equity, the increasing liabilities pose a risk to financial stability.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow in recent years, highlighting liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating a struggle to convert income into cash. Consistently negative free cash flow growth raises concerns about the company’s ability to sustain operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.03B	3.81B	4.58B	6.28B	6.77B	5.55B
Gross Profit	973.81M	-685.16M	1.33B	2.27B	2.86B	2.10B
EBITDA	-271.65M	-662.07M	-2.69M	893.14M	1.65B	1.19B
Net Income	-1.28B	-1.35B	-469.30M	255.65M	898.59M	650.49M
Balance Sheet
Total Assets	0.00	8.81B	9.75B	9.79B	8.97B	6.78B
Cash, Cash Equivalents and Short-Term Investments	5.75M	8.55M	16.47M	27.54M	33.44M	15.42M
Total Debt	0.00	5.55B	4.94B	3.41B	2.79B	1.87B
Total Liabilities	-2.35B	6.46B	6.05B	5.60B	5.00B	3.68B
Stockholders Equity	2.35B	2.35B	3.69B	4.19B	3.96B	3.09B
Cash Flow
Free Cash Flow	0.00	-302.20M	-1.25B	-426.03M	-803.74M	-1.11B
Operating Cash Flow	0.00	-83.99M	102.21M	746.56M	236.04M	-81.62M
Investing Cash Flow	0.00	-152.30M	-1.35B	-1.13B	-1.04B	-731.10M
Financing Cash Flow	0.00	237.33M	1.25B	377.70M	804.77M	813.36M

Astec Lifesciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 703.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 703.5 is above the 20-day moving average (MA) of 627.41, below the 50-day MA of 708.50, and below the 200-day MA of 763.98, indicating a bearish trend. The MACD of -35.54 indicates Positive momentum. The RSI at 29.66 is Positive, neither overbought nor oversold. The STOCH value of 17.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PUNJABCHEM	64 Neutral	₹14.91B	24.83	―	0.24%	10.70%	32.65%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
IOLCP	60 Neutral	₹21.72B	18.75	―	0.97%	5.74%	16.06%
IGPL	59 Neutral	₹11.16B	34.33	―	2.59%	-10.71%	-40.89%
ASTEC	52 Neutral	₹12.80B	-13.28	―	―	1.54%	-8.04%
UNIENTER	49 Neutral	₹7.99B	42.10	―	0.34%	―	―
HERANBA	44 Neutral	₹8.77B	-18.65	―	0.39%	―	―

Astec Lifesciences Limited Corporate Events

Astec LifeSciences Files SEBI Demat Compliance Certificate for December Quarter

Astec LifeSciences Limited has informed the Indian stock exchanges that it has received a compliance certificate from its registrar and share transfer agent, Bigshare Services Pvt. Ltd., for the quarter ended 31 December 2025, confirming adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The registrar has certified that no securities were received for dematerialisation during the quarter, and therefore no share certificates were mutilated, cancelled or had their ownership substituted in favour of depositories, underscoring a period of no demat-related activity and reinforcing the company’s ongoing regulatory compliance in its securities handling processes.